As the entire world is suffering from the impact of coronavirus, biopharma and biotech industry are also experiencing unprecedented situations, including remote work model and reduced lab capacity.
A shift in focus to development of vaccine and antiviral therapies has slowed the fight against cancer and cancer research. However, cancer still remains a disease that deserves attention and no interruption. More frequently than before the pandemic, R&D biopharma are outsourcing preclinical studies to enable continuity of their programs.
At Beviglia Cancer Models we have been fully operational to help our clients meet their projects goals with timely delivery of high quality results. Do not miss the opportunity to talk with us and learn about our preclinical cancer pharmacology capabilities to advance your drug discoveries.
Cancer Research During the Pandemic
